Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
Status:
Completed
Trial end date:
2006-08-31
Target enrollment:
Participant gender:
Summary
Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid
tumors. The purpose of this study is to assess the efficacy and safety of
irofulven/capecitabine combination therapy in patients with anaplastic, medullary, or locally
advanced/metastatic differentiated thyroid cancer.